 T1D is a chronic disease with high morbidity and mortality but with preserved beta-cells there are less hypoglycemic events and less progression in late complications 1, therefore the preservation and expansion of beta-cells is a goal. Intervention studies in type 1 patients have primarily focused on immune suppressing or immune modulation 2. Most of those studies have several and serious side effects or no effect on preserving or expanding the number of beta cells. 